Figure 1.

Visfatin increases the TYMS expression in human DLD-1 CRC cells. Human DLD-1 CRC cells were kept as control (CL) or (A,C) treated with visfatin (50 ng/mL) for 6, 12, and 24 h or (B,D) treated with different doses of visfatin (25, 50, and 100 ng/mL) for 12 h. The mRNA (A,B) and protein (C,D) expressions of TYMS of were examined by real-time PCR and Western blot, respectively. Data in (A,B) were shown as mean ± SEM from three independent experiments. Results in (C,D) were representative of three independent experiments with similar results. p < 0.05 was defined as statistically significant.